Skip to content
Fortis Healthcare logo

Fortis Healthcare

FORTIS NSE
₹825.00 +15.15 (+1.87%)
Market Cap
₹62,284 Cr
P/E
59.96
View as Markdown
MCP
Close 20 Nov 2026 ₹825.00 1Y −97.20 −10.5%
Start ₹922.20

Key Fundamentals

MidcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
13.40%
Debt to Equity
0.30
EPS (TTM)
₹13.76
Book Value
₹138.79
Market Cap
₹62,284 Cr
P/E (TTM)
59.96
P/B
5.94
ROE
11.20%
Dividend Yield
0.12%
EBITDA
₹2,136 Cr
52W High
₹1,010.10
52W Low
₹704.95
Day Range
₹802.40 – ₹829.00
Volume
22,88,213

Peer Comparison

Healthcare › Healthcare Services › Hospital

Fortis Healthcare peer comparison
9,200.0059.001,32,28212.470.23%21.50%17.40%27,6302,337
1,081.0076.231,05,2159.280.20%14.70%14.70%9,1461,380
702.20101.7792,3666.010.00%6.72%8.30%12,370873
779.30110.7067,9298.720.41%11.30%11.60%6,508564
Fortis Healthcare (this company)
825.0059.9662,2845.940.13%11.20%13.40%9,9101,061
1,480.2064.3339,7989.200.03%15.20%17.40%5,053613
1,943.7046.2539,7227.940.24%20.50%15.50%10,273859
Median 7 companies1,081.0064.3367,9298.720.20%14.70%14.70%9,910873

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 100/100

Category scores

Quality
47
Average
Returns, margins, earnings quality 22% weight
Valuation
40
Weak
Cheap vs sector & own history 24% weight
Growth
52
Average
Sales & profit trajectory 9% weight
Financial Health
34
Poor
Solvency, leverage, coverage 9% weight
Momentum
11
Poor
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 64.3% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 5.94 times its book value
  • Company has a low return on equity of 9.87% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish748
OscillatorsBearish342
Moving AveragesStrong Bullish406

Key readings

RSI (14)
60.58
Neutral
MACD (12,26,9)
5.62
Bullish
SMA (50)
798.09
Bullish
SMA (200)
889.57
Bearish

As of

Analyst Rating

Based on 17 analysts
BUY82%

14 of 17 analysts rate Buy, 3 Hold, 0 Sell.

As of

BUY
14
82%
HOLD
3
18%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+8.07%
5Y+17.76%
3Y+13.17%
1Y+17.28%
TTM+17.51%

Net profit

Net profit growth by window
10Y+38.16%
5YTurned to profit
3Y+18.90%
1Y+31.52%
TTM+2.22%

Operating cash flow

Operating cash flow growth by window
10Y+23.43%
5Y+26.98%
3Y+24.88%
1Y+12.43%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+20.65 pp
5Y+12.82 pp
3Y+5.36 pp
1Y+2.44 pp
TTM+0.16 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹4,574 Cr
Mar 2018₹4,561 Cr
Mar 2019₹4,469 Cr
Mar 2020₹4,632 Cr
Mar 2021₹4,030 Cr
Mar 2022₹5,718 Cr
Mar 2023₹6,298 Cr
Mar 2024₹6,893 Cr
Mar 2025₹7,783 Cr
Mar 2026₹9,128 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹479 Cr
Mar 2018−₹934 Cr
Mar 2019−₹224 Cr
Mar 2020₹91.00 Cr
Mar 2021−₹56.00 Cr
Mar 2022₹790 Cr
Mar 2023₹633 Cr
Mar 2024₹645 Cr
Mar 2025₹809 Cr
Mar 2026₹1,064 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹588 Cr −8.0% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 17 Nov 2026
AI opinion · based on fundamentals
Risk high

Fortis Healthcare Ltd trades at ₹806.8 as of 2026-11-17 with a market cap of ₹60,910 Cr. The company has delivered strong 5-year profit CAGR of 64% and 5-year sales CAGR of 18%, but the stock trades at a P/E of 58.63x and 5.81x book value, while return on equity stands at 10.47%. The stock is down roughly 20% from its 52-week high of ₹1,010.1.

Bull Case 7
  • Strong long-term profit compounding: 5-year compounded profit growth of 64%, reflecting a significant improvement in earnings power over the medium term.
  • Healthy revenue momentum: TTM sales growth of 18% and 5-year compounded sales growth of 18% indicate sustained top-line expansion.
  • Improving return on equity trajectory: ROE has risen from a 10-year average of 5% to 11% in the last year, showing improving capital efficiency.
  • Conservative leverage: Debt-to-equity ratio of 0.34 provides financial flexibility and limits balance sheet risk for a capital-intensive hospital business.
  • Solid long-term stock performance: 10-year stock CAGR of 18% and 5-year CAGR of 23% demonstrate sustained wealth creation over extended periods.
  • Double-digit ROCE: Return on capital employed of 12.13% suggests the company is generating reasonable returns above its cost of debt on deployed capital.
  • 10-year compounded sales growth of 8% combined with 10-year compounded profit growth of 60% indicates significant operating leverage and margin expansion over the long term.
Bear Case 6
  • High price-to-book multiple: Trading at 5.81x book value implies a heavy premium to net assets, which could compress if profitability plateaus.
  • Slowing profit growth: TTM profit growth has decelerated sharply to 7% compared to the 5-year CAGR of 64%, raising questions about sustainability of high earnings multiples.
  • Negligible dividend yield: At 0.12%, the dividend yield offers virtually no income return to shareholders, making the stock entirely dependent on capital appreciation.
  • Negative 1-year stock return: The stock has declined 13% over the past year and is trading roughly 20% below its 52-week high of ₹1,010.1, indicating weakening sentiment.
  • Moderate ROE relative to valuation: ROE of 10.47% is modest for a stock commanding nearly 59x earnings, suggesting the premium is not fully justified by current profitability.
  • 3-year average ROE of approximately 10% remains below levels typically expected for companies trading at such elevated valuation multiples in the healthcare sector.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Fortis Healthcare is executing well on both organic and inorganic fronts, posting 17.3% revenue growth in Q2FY27 while aggressively expanding its Bengaluru cluster through the ₹277 crore Suguna Hospital acquisition. The CGIO departure is a watch item but not a structural concern. No material headwinds are visible in recent news flow, and the trend appears firmly positive with continued capacity expansion likely to support future growth.

Positives 2
  • Q2FY27 revenue up 17.3% Nov 5

    Consolidated revenue rose 17.3% YoY to ₹2,735 crore in Q2FY27, driven by strong hospital business growth and diagnostics expansion.

  • Suguna Hospital acquired for ₹277Cr Oct 28

    Fortis acquired Suguna Hospital in Bengaluru for ₹277 crore via subsidiary IHL, adding 110 beds (expandable to 150) and taking Bengaluru capacity to ~1,000 beds. The deal valued at ~5.6x EV/revenue follows the People Tree Hospital purchase in Jan 2026, giving Fortis ~500 potential beds in the north-west Bengaluru corridor.

Neutral 1
  • CGIO Ritu Garg resigns Oct 31

    Chief Growth & Innovation Officer Dr. Ritu Garg resigned effective October 31, 2026, citing a professional opportunity outside the organization.

Quarterly Results

₹ Cr
FORTIS quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
1,770
1,680
1,786
1,859
1,988
1,928
2,007
2,167
2,331
2,265
2,365
2,545
2,735
Expenses
1,440
1,396
1,405
1,516
1,554
1,553
1,572
1,676
1,775
1,759
1,832
2,008
2,112
Operating Profit
330
284
381
343
435
375
435
491
556
506
532
537
623
OPM %
19%
17%
21%
18%
22%
19%
22%
23%
24%
22%
23%
21%
23%
Other Income
18
19
17
13.01
−42
47
−29
31
50
−34
−2
28
16
Interest
32
33
35
35
36
45
68
70
75
86
84
80
78.3
Depreciation
84
87
92
91
95
97
102
101
106
120
122
122
128
PBT
231
183
271
229
261
279
237
351
425
266
324
363
432
Tax %
21%
27%
25%
24%
26%
9%
21%
24%
23%
26%
16%
25%
26%
Net Profit
184
134
203
174
193
254
188
267
329
197
271
273
320
EPS (₹)
2.30
1.78
2.37
2.20
2.34
3.28
2.44
3.45
4.26
2.57
3.52
3.53
4.14
YoY Sales growth
10
8
9
12
12
15
12
17
17
17
18
17
17

Profit & Loss

₹ Cr
FORTIS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,966
4,199
4,574
4,561
4,469
4,632
4,030
5,718
6,298
6,893
7,783
9,128
9,910
Expenses
3,857
4,106
4,220
4,287
4,238
4,022
3,626
4,649
5,196
5,625
6,195
7,043
7,711
Operating Profit
109
92
354
274
231
610
404
1,069
1,101
1,268
1,588
2,085
2,198
OPM %
2.8%
2.2%
8%
6%
5%
13%
10%
19%
17%
18%
20%
23%
22%
Other Income
92
299
649
−689
228
126
95
367
157
64
−11
45
8
Interest
152
133
229
258
337
205
166
147
129
131
184
314
329
Depreciation
235
225
222
239
233
292
291
301
316
342
386
449
492
PBT
−185
34
552
−912
−110
239
43
988
814
858
1,007
1,366
1,385
Tax %
2%
−24%
13%
2%
103%
62%
230%
20%
22%
25%
20%
22%
—
Net Profit
−130
42
479
−934
−224
91
−56
790
633
645
809
1,064
1,062
EPS (₹)
−3.10
0.40
8.14
−19.46
−3.96
0.77
−1.45
7.35
7.80
7.93
10.26
13.80
13.76
Div. Payout %
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
0%
0%
0%
0%
0%
0%
0%
13%
13%
10%
7%
—
Sales growth
14
6
9
0
−2
4
−13
42
10
9
13
17
18

Balance Sheet

₹ Cr
FORTIS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
463
463
518
519
755
755
755
755
755
755
755
755
755
Reserves
3,585
3,998
4,626
3,543
5,846
5,906
5,365
5,423
6,487
6,908
8,162
9,141
9,723
Borrowings
1,784
1,513
2,217
1,962
2,010
1,594
1,531
1,255
926
1,155
2,475
3,473
3,164
Other Liabilities
1,760
1,257
2,227
2,455
2,875
2,781
3,216
4,082
3,921
4,153
1,985
2,465
2,772
Total Liabilities
7,592
7,232
9,588
8,479
11,486
11,036
10,866
11,516
12,089
12,971
13,377
15,833
16,415
Fixed Assets
4,218
3,642
5,419
4,992
8,477
8,802
8,799
9,416
9,426
9,874
10,424
12,230
12,373
CWIP
228
226
268
226
450
204
165
193
228
542
407
434
495
Investments
1,464
1,452
1,878
1,732
270
175
186
104
210
230
169
243
254
Other Assets
1,682
1,913
2,023
1,529
2,290
1,856
1,716
1,803
2,225
2,326
2,378
2,926
3,292
Total Assets
7,592
7,232
9,588
8,479
11,486
11,036
10,866
11,516
12,089
12,971
13,377
15,833
16,415

Cash Flow

₹ Cr
FORTIS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
24
195
966
493
−179
172
485
865
822
1,100
1,424
1,601
Investing
213
122
−1,001
−333
−3,279
63
−131
−501
−372
−889
−780
−1,537
Financing
−304
−354
259
−672
4,257
−862
−143
−517
−471
−86
−714
164
Net Cash Flow
−66
−37
225
−513
799
−627
212
−153
−21
125
−70
228
Free Cash Flow
−181
−162
689
437
−261
35
274
750
367
172
591
673
CFO/EBITDA
131
354
304
187
30
84
108
101
100
104
97
90

Ratios

FORTIS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
38
39
38
38
44
36
41
33
34
33
37
42
Inventory Days
25
23
23
24
22
30
29
33
31
24
23
24
Days Payable
207
218
215
279
296
226
205
178
179
164
161
165
Cash Conversion Cycle
−144
−156
−155
−217
−230
−161
−135
−112
−115
−107
−101
−99
Working Capital Days
−71
−69
−87
−113
−234
−150
−56
−35
−22
−124
−30
−34
ROCE %
0%
3%
11%
3%
6%
4%
2%
10%
10%
10%
12%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Fortis Healthcare insights

64 extracted metrics across FY13–FY27.

Shareholding Pattern

As of Sep 2026

  • DIIs 34.46%
  • Promoters 31.17%
  • FIIs 23.19%
  • Public 9.80%
  • Others 1.38%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Fortis Healthcare

What does Fortis Healthcare Ltd do?
FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India.
Where is Fortis Healthcare Ltd (FORTIS) listed?
Fortis Healthcare Ltd trades as FORTIS on the NSE and under code 532843 on the BSE.
Which sector does Fortis Healthcare Ltd belong to?
Fortis Healthcare Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Fortis Healthcare Ltd?
Fortis Healthcare Ltd has a market capitalisation of ₹62,284 Cr as of 20 Nov 2026, which places it in the Midcap band.
What is the PE ratio of Fortis Healthcare Ltd?
Fortis Healthcare Ltd trades at a PE ratio of 59.96 as of 20 Nov 2026, on earnings per share of ₹13.76, against a book value of ₹138.79 per share.
What is the 52-week high and low of Fortis Healthcare Ltd?
Over the last 52 weeks Fortis Healthcare Ltd has traded between ₹704.95 and ₹1,010.1 as of 20 Nov 2026.
Does Fortis Healthcare Ltd pay dividends?
Fortis Healthcare Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Fortis Healthcare Ltd?
Fortis Healthcare Ltd reported a return on equity of 11.20%. Its debt-to-equity ratio is 0.30.

Company Information

FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. Company controls its diagnostics business through its 57% owned subsidiary SRL Limited. It is amongst the largest private diagnostics chains. It has a presence in over 600 cities and towns, with an established strength of 415 laboratories, 8,200 direct clients and 1,400 Collection Centers.

CEO Dr. Ashutosh Raghuvanshi
Employees 12,237
Listed 9 May 2007
Face Value ₹10
Shares Outstanding 75,49,58,148

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/FORTIS.md for Fortis Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More